JARED BROCK: Open Payments
NPI 1073551248 · COLUMBUS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$999 in 59 payments from 22 companies in 2025. Trend: 2023 $849 · 2024 $649 · 2025 $999
Food & beverage: $999
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $162 |
| GlaxoSmithKline, LLC. | 11 | $139 |
| Novo Nordisk Inc | 9 | $136 |
| Vanda Pharmaceuticals Inc. | 3 | $78 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $55 |
| Corium, LLC | 3 | $52 |
| Lilly USA, LLC | 3 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
Products named: VRAYLAR, TRELEGY ELLIPTA, FANAPT, Wegovy, JARDIANCE, Ozempic, Azstarys, TRINTELLIX.
Industry payments across IN — which companies pay providers there.
